Post-2009, PRPH went through a complete strategic overhaul that pushed this biotech company into the growth phase we continue to see today. After a tough proxy battle in 2009, the founder stepped down, and Ted Karkus has been CEO ever since. was created to focus on R&D for further drug development programs. It IPOd in 1991, and it was best known for its cold remedy, the over-the-counter Cold-Eeze product, which was established in 1992 and has since been sold to Mylan Pharma. PRPH was established in 1989 and originally named The Quigley Corp., after its founder, former CEO and Chairman Guy J. Due to this stock being cheap, undervalued and well-performing, I believe investors may want to take a bullish stance on this company. It has increased its top and bottom line performance year on year, grown its working capital, paid special dividends, and made strategic acquisitions for continued growth opportunities. I believe there is much more upside potential for this cheap biotech company with solid fundamentals. The company has outperformed the market to date, and the stock price is currently well below the one-year target of $15. Over the last three years, the compound annual revenue has grown by 132.07%. PRPH is a longstanding biotech company which had a complete strategic company overhaul in late 2009. The company has beaten earning expectations for the previous three consecutive quarters. Over the last year, the stock price has increased by 114.03%. ( NASDAQ: PRPH) is small-cap biotech stock with a market cap of only $174.74 million.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |